U.S. Markets closed

Artelo Biosciences, Inc. (ARTL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8500+0.0432 (+5.35%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8068
Open0.8444
Bid0.8330 x 1300
Ask0.8500 x 3000
Day's Range0.8209 - 0.8598
52 Week Range0.4510 - 3.6700
Volume319,962
Avg. Volume373,630
Market Cap19.677M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)-0.6000
Earnings DateApr 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    SOLANA BEACH, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021. Artelo’s presentation will be

  • Newsfile

    Artelo Biosciences to Present at the Q3 Virtual Investor Summit on August 18th

    Solana Beach, California--(Newsfile Corp. - August 11, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that management will present at the Q3 Virtual Investor Summit, hosted by the Investor Summit Group, being held virtually on August 17-18, 2021.Andrew Yates, PhD, Senior Vice President and Chief Scientific Officer is s

  • GlobeNewswire

    Artelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines

    Study finds no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD Study further validates Artelo’s strategy to develop a synthetic CBD-cocrystal with enhanced pharmaceutical properties as well as synergistic use of the coformer TMP SOLANA BEACH, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of the